Long-term iloprost therapy has possible disease-modifying effects in Raynaud's phenomenon

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1316, 2001-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 512-519

Bentham Science Publishers

Access to resources Recommend Favorite

Iloprost: Paradoxical reaction of Raynaud Phenomenon: case report

By  

Reactions Weekly, Vol. 1, Iss. 1433, 2013-01 ,pp. : 25-26

Adis International

Access to resources Recommend Favorite

Donepezil: potential neuroprotective and disease-modifying effects

By Jacobson Sandra A   Sabbagh Marwan N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 10, 2008-10 ,pp. : 1363-1369

Informa Healthcare

Access to resources Recommend Favorite

Long-term statin therapy: no negative effects on IMT

By  

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 26-26

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

By Amato Maria Pia  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2115-2126

Informa Healthcare

Access to resources Recommend Favorite